Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease - PubMed (original) (raw)
. 2013 Jul;260(7):1724-30.
doi: 10.1007/s00415-013-6851-0. Epub 2013 Feb 12.
Roberto Erro, Gabriella Santangelo, Rosario Pivonello, Katia Longo, Claudia Pivonello, Carmine Vitale, Marianna Amboni, Marcello Moccia, Annamaria Colao, Paolo Barone, Maria Teresa Pellecchia
Affiliations
- PMID: 23400497
- DOI: 10.1007/s00415-013-6851-0
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease
Marina Picillo et al. J Neurol. 2013 Jul.
Abstract
Much pre-clinical evidence show that insulin-like growth factor 1 (IGF-1) provides protection against loss of dopaminergic neurons. Recently, IGF-1 has been proposed as a possible biomarker for early diagnosis of Parkinson's disease (PD). We aimed to assess the relationship between serum IGF-1 levels and progression of motor symptoms in a cohort of drug-naïve PD patients. Serum IGF-1 was measured at baseline in 37 early, drug-naive PD patients; subsequently, patients were evaluated "on drug" by means of UPDRS-III, UPDRS dopa-resistant score and dopaminergic score at 12, 18 and 24 month follow-up. Repeated measures ANOVA was used both to evaluate progression of motor scores within time and differences between serum IGF-1 quartiles, age at onset and motor phenotype. Patients at the highest IGF-1 quartile were found to have significantly higher UPDRS-III (p < 0.001) and dopaminergic score (p < 0.001), as compared to patients at other quartiles. Mean serum IGF-1 level was moderately increased in PD as compared to healthy controls (p < 0.011). IGF-1 levels are related to those symptoms predominantly responsive to dopaminergic treatment. This is the first study to demonstrate a relationship between serum IGF-1 and progression of motor symptoms in the early stage of disease.
Similar articles
- Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease.
Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Godau J, et al. J Neurol Neurosurg Psychiatry. 2010 May;81(5):536-8. doi: 10.1136/jnnp.2009.175752. Epub 2010 Feb 22. J Neurol Neurosurg Psychiatry. 2010. PMID: 20176597 - Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Numao A, Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Numao A, et al. Parkinsonism Relat Disord. 2014 Feb;20(2):212-6. doi: 10.1016/j.parkreldis.2013.11.005. Epub 2013 Nov 14. Parkinsonism Relat Disord. 2014. PMID: 24280021 - Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.
Bernhard FP, Heinzel S, Binder G, Weber K, Apel A, Roeben B, Deuschle C, Maechtel M, Heger T, Nussbaum S, Gasser T, Maetzler W, Berg D. Bernhard FP, et al. PLoS One. 2016 Mar 11;11(3):e0150552. doi: 10.1371/journal.pone.0150552. eCollection 2016. PLoS One. 2016. PMID: 26967642 Free PMC article. - Is insulin-like growth factor-1 involved in Parkinson's disease development?
Castilla-Cortázar I, Aguirre GA, Femat-Roldán G, Martín-Estal I, Espinosa L. Castilla-Cortázar I, et al. J Transl Med. 2020 Feb 11;18(1):70. doi: 10.1186/s12967-020-02223-0. J Transl Med. 2020. PMID: 32046737 Free PMC article. Review. - Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S; Parkinson Study Group. Fahn S, et al. J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
Cited by
- Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure.
Ghazi Sherbaf F, Mohajer B, Ashraf-Ganjouei A, Mojtahed Zadeh M, Javinani A, Sanjari Moghaddam H, Shirin Shandiz M, Aarabi MH. Ghazi Sherbaf F, et al. Front Endocrinol (Lausanne). 2018 Nov 2;9:608. doi: 10.3389/fendo.2018.00608. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30450079 Free PMC article. - Meta-analyses of seven GIGYF2 polymorphisms with Parkinson's disease.
Dai D, Wang Y, Zhou X, Tao J, Jiang D, Zhou H, Jiang Y, Pan G, Ru P, Ji H, Li J, Zhang Y, Yin H, Xu M, Duan S. Dai D, et al. Biomed Rep. 2014 Nov;2(6):886-892. doi: 10.3892/br.2014.324. Epub 2014 Jul 31. Biomed Rep. 2014. PMID: 25279164 Free PMC article. - 40 YEARS of IGF1: IGF1: the Jekyll and Hyde of the aging brain.
Gubbi S, Quipildor GF, Barzilai N, Huffman DM, Milman S. Gubbi S, et al. J Mol Endocrinol. 2018 Jul;61(1):T171-T185. doi: 10.1530/JME-18-0093. Epub 2018 May 8. J Mol Endocrinol. 2018. PMID: 29739805 Free PMC article. Review. - Supplementation of Blackcurrant Anthocyanins Increased Cyclic Glycine-Proline in the Cerebrospinal Fluid of Parkinson Patients: Potential Treatment to Improve Insulin-Like Growth Factor-1 Function.
Fan D, Alamri Y, Liu K, MacAskill M, Harris P, Brimble M, Dalrymple-Alford J, Prickett T, Menzies O, Laurenson A, Anderson T, Guan J. Fan D, et al. Nutrients. 2018 Jun 2;10(6):714. doi: 10.3390/nu10060714. Nutrients. 2018. PMID: 29865234 Free PMC article. Clinical Trial. - Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson's disease.
Zhang HY, Jiang YC, Li JR, Yan JN, Wang XJ, Shen JB, Ke KF, Gu XS. Zhang HY, et al. Neural Regen Res. 2023 May;18(5):1099-1106. doi: 10.4103/1673-5374.355815. Neural Regen Res. 2023. PMID: 36254999 Free PMC article.
References
- J Neural Transm Park Dis Dement Sect. 1995;9(2-3):177-88 - PubMed
- Neurology. 2008 Aug 26;71(9):670-6 - PubMed
- J Neurol Neurosurg Psychiatry. 2010 May;81(5):536-8 - PubMed
- Biofactors. 2008;33(2):99-106 - PubMed
- Arch Neurol. 2005 Mar;62(3):467-72 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous